UPDATE 1-Actelion sees Uptravi price of $160,000-170,000/patient
January 05, 2016 at 12:21 PM EST
ZURICH, Jan 5 (Reuters) - Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, Chief Operating Officer Otto Schwarz told analysts on Tuesday.
